Patents by Inventor Tsuyoshi Shimoboji

Tsuyoshi Shimoboji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190142959
    Abstract: The present invention provides hyaluronic acid derivatives into which a certain cationic group and a certain hydrophobic group are introduced, the hyaluronic acid derivatives including one or more repeating units represented by the formula (Ia) and one or more repeating units represented by the formula (Ib).
    Type: Application
    Filed: May 11, 2017
    Publication date: May 16, 2019
    Inventors: Takashi NAKAI, Teruo NAKAMURA, Sayan CHUANOI, Hideyuki TOGAWA, Tsuyoshi SHIMOBOJI, Kazuo HATTORI, Takashi EMURA
  • Patent number: 9394379
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: July 19, 2016
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Patent number: 9243077
    Abstract: The present invention provides a hyaluronic acid derivative comprising disaccharide units of Formula (I), and a hyaluronic acid derivative/drug conjugate wherein one or more drugs are conjugated to the hyaluronic acid derivative.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: January 26, 2016
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoko Yasugi, Yoshihiro Tampo, Kenji Yasugi, Tai Hirakura, Tsuyoshi Shimoboji
  • Publication number: 20150231268
    Abstract: The present invention provides a hyaluronic acid derivative containing a disaccharide unit represented by formula (I) or formula (I) and (II), and a complex containing the hyaluronic acid derivative and a drug.
    Type: Application
    Filed: September 5, 2013
    Publication date: August 20, 2015
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Takashi Nakai, Tomoko Yasugi, Yoshihiro Tampo, Kenji Yasugi, Tsuyoshi Shimoboji
  • Patent number: 8987230
    Abstract: The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s) in the presence of the hydrophilic polysaccharide derivative wherein the hydrophilic polysaccharide derivative may have a crosslinkable group(s).
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: March 24, 2015
    Assignees: National University Corporation Tokyo Medical and Dental University, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kazunari Akiyoshi, Nobuyuki Morimoto, Tai Hirakura, Tsuyoshi Shimoboji
  • Patent number: 8759322
    Abstract: The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): wherein R1, R2, R3, R4, Z, n, Ra, Y, and X1 are as defined in the specification.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: June 24, 2014
    Assignees: National University Corporation Tokyo Medical and Dental University, Chugau Seiyaku Kabushiki Kaisha
    Inventors: Kazunari Akiyoshi, Takashi Nakai, Tai Hirakura, Tsuyoshi Shimoboji
  • Publication number: 20140011991
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Application
    Filed: July 22, 2013
    Publication date: January 9, 2014
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kenji YASUGI, Teruo NAKAMURA, Tsuyoshi SHIMOBOJI, Mika SATO
  • Publication number: 20130338352
    Abstract: The present invention provides a hyaluronic acid derivative comprising disaccharide units of Formula (I), and a hyaluronic acid derivative/drug conjugate wherein one or more drugs are conjugated to the hyaluronic acid derivative.
    Type: Application
    Filed: March 2, 2012
    Publication date: December 19, 2013
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoko Yasugi, Yoshihiro Tampo, Kenji Yasugi, Tai Hirakura, Tsuyoshi Shimoboji
  • Patent number: 8575332
    Abstract: The present invention provides long-acting sustained-release formulations of drugs such as proteins or peptides, which are injectable, completely biodegradable and safe, as well as ensuring efficient encapsulation of the drugs such as proteins or peptides without inhibiting their biological activity. It is possible to achieve injectable sustained-release formulations that ensure efficient encapsulation and long-term sustained release of drugs such as proteins or peptides while retaining their biological activity, when a solution containing a drug and a polysaccharide derivative such as hyaluronic acid having a crosslinkable functional group(s) or a salt thereof is dehydrated in microparticulate form starting from a dilute state, where crosslinking proceeds slowly, to reach a concentration which facilitates crosslinking, to thereby cause crosslinking reaction during concentration, so that the drug is encapsulated into the crosslinked polysaccharide to give drug-carrying microparticles.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 5, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Sei Kwang Hahn, Tsuyoshi Shimoboji
  • Publication number: 20120183567
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Application
    Filed: March 26, 2012
    Publication date: July 19, 2012
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kenji YASUGI, Teruo NAKAMURA, Tsuyoshi SHIMOBOJI, Mika SATO
  • Patent number: 8143391
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: March 27, 2012
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Publication number: 20110212901
    Abstract: The present invention provides a hydrophobic group-introduced hyaluronic acid derivative comprising at least one repeating unit represented by the formula (I): wherein R1, R2, R3, R4, Z, n, Ra, Y, and X1 are as defined in the specification.
    Type: Application
    Filed: November 5, 2009
    Publication date: September 1, 2011
    Applicants: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kazunari Akiyoshi, Takashi Nakai, Tai Hirakura, Tsuyoshi Shimoboji
  • Patent number: 7816316
    Abstract: The present invention aims to provide completely biodegradable and biocompatible sustained-release carriers for proteins or peptides, which allow encapsulation of the proteins or peptides at high encapsulation rates without inhibiting their biological activity. The present invention provides a method for preparing a sustained-release carrier, wherein in a solution in the presence of a protein or a peptide, a hyaluronic acid derivative having an unsaturated bond(s) or a mercapto group(s) introduced into hyaluronic acid is chemically crosslinked with a mercapto group-containing compound or an unsaturated bond-containing compound, respectively, to give a hydrogel. The method of the present invention enables efficient encapsulation of proteins or peptides while retaining their biological activity.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: October 19, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Sei Kwang Hahn, Teruo Nakamura, Tsuyoshi Shimoboji
  • Publication number: 20100204102
    Abstract: The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s) in the presence of the hydrophilic polysaccharide derivative wherein the hydrophilic polysaccharide derivative may have a crosslinkable group(s).
    Type: Application
    Filed: April 30, 2008
    Publication date: August 12, 2010
    Inventors: Kazunari Akiyoshi, Nobuyuki Morimoto, Tai Hirakura, Tsuyoshi Shimoboji
  • Patent number: 7767806
    Abstract: A hyaluronic acid modification product includes a polymer bonded to hyaluronic acid, the polymer being polylactic acid, polyglycolic acid or lactic acid-glycolic acid copolymer, providing a drug carrier which efficiently encapsulates low molecular weight drugs and provides sustained-release over a long term, control of blood residence, is well dispersible in an aqueous solution, and has excellent biocompatibility.
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: August 3, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tai Hirakura, Teruo Nakamura, Tsuyoshi Shimoboji
  • Patent number: 7625764
    Abstract: Conjugates that include polymers that are reversibly self-associative in response to a stimulus and methods for using the conjugates.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: December 1, 2009
    Assignee: University of Washington
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Noah Malmstadt, Tsuyoshi Shimoboji, Samarth Kulkarni
  • Publication number: 20090286724
    Abstract: The present invention provides a GLP-1 analogue having a high association-aggregability or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition to be used for preventing or treating diabetes, hyperglycemia, a diabetic complication caused by diabetes or hyperglycemia, or obesity, using the same.
    Type: Application
    Filed: October 26, 2006
    Publication date: November 19, 2009
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Hiroko Konishi, Tomoyuki Igawa, Tsuyoshi Shimoboji, Tai Hirakura
  • Publication number: 20090193826
    Abstract: There is provided a temperature switching compartment 3 which can switch the internal temperature thereof between a low temperature side at which a storage material is kept in cold storage and a high temperature side maintained at 50° C., to 80° C. at which cooked food is kept warm, by cooling with a cooler 17 and heating with a heater 15.
    Type: Application
    Filed: September 7, 2005
    Publication date: August 6, 2009
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Publication number: 20090148534
    Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction rate of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction rate as that of the conventionally known gel.
    Type: Application
    Filed: September 7, 2005
    Publication date: June 11, 2009
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
  • Publication number: 20090082266
    Abstract: To provide a GLP-1 analogue long-acting prophylactic or therapeutic agent for diabetes, diabetic complications and/or obesity due to diabetes which provides an extended half-life of a GLP-1 analogue in the blood to prevent frequent administration, and is biodegradable and safe. The present invention provides a conjugate obtained by binding, to a GLP-1 analogue into which a mercapto group is incorporated, water soluble hyaluronic acid modification product obtained by incorporating a substituent via an amide bond to the carboxyl group of glucuronic acid portion of hyaluronic acid as a derivative thereof, using a specific condensing agent in an aprotic polar solvent; and a prophylactic or therapeutic agent having a durable blood glucose lowering effect for diabetes, diabetic complications or obesity.
    Type: Application
    Filed: March 8, 2006
    Publication date: March 26, 2009
    Inventors: Teruo Nakamura, Tatsuya Kato, Hideyuki Togawa, Kenji Yasugi, Hiroko Konishi, Yasuo Sekimori, Tsuyoshi Shimoboji